X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (202) 202
life sciences & biomedicine (197) 197
humans (168) 168
male (127) 127
female (126) 126
adult (100) 100
middle aged (88) 88
treatment outcome (74) 74
infectious diseases (73) 73
treatment-naive (63) 63
treatment-naïve (60) 60
hiv infections - drug therapy (59) 59
hiv (50) 50
aged (48) 48
treatment naïve (46) 46
immunology (43) 43
virology (43) 43
hiv infections - virology (42) 42
human immunodeficiency virus--hiv (42) 42
drug therapy (40) 40
aids/hiv (38) 38
hiv-1 (37) 37
adolescent (36) 36
young adult (34) 34
treatment naive (31) 31
antiretroviral drugs (30) 30
health aspects (30) 30
viral load (30) 30
oncology (28) 28
anti-hiv agents - therapeutic use (26) 26
pharmacology & pharmacy (26) 26
care and treatment (25) 25
hiv infection (25) 25
clinical trials (23) 23
drug resistance (23) 23
drug therapy, combination (23) 23
genotype (23) 23
antiretroviral therapy (22) 22
research (22) 22
virus diseases (22) 22
analysis (21) 21
antiviral agents (21) 21
efavirenz (21) 21
gastroenterology & hepatology (21) 21
mutation (21) 21
patients (21) 21
treatment-naive patients (21) 21
antiviral agents - therapeutic use (20) 20
cd4 lymphocyte count (20) 20
anti-hiv agents - adverse effects (19) 19
hepatitis c, chronic - drug therapy (19) 19
hiv-1 - drug effects (19) 19
hiv-1 - isolation & purification (19) 19
medical research (19) 19
medicine (19) 19
rna, viral - blood (19) 19
double-blind method (18) 18
hepatitis c (18) 18
hepatitis c virus (18) 18
protease inhibitors (18) 18
psychiatry (18) 18
retrospective studies (18) 18
drug resistance, viral (17) 17
hiv-1 - genetics (17) 17
treatment-naïve patients (17) 17
hepacivirus - genetics (16) 16
interferon (16) 16
studies (16) 16
tenofovir (16) 16
adenine - analogs & derivatives (15) 15
antiretroviral therapy, highly active - methods (15) 15
medicine, experimental (15) 15
microbiology (15) 15
reverse transcriptase inhibitors - therapeutic use (15) 15
acquired immune deficiency syndrome--aids (14) 14
anti-hiv agents - administration & dosage (14) 14
hepatitis (14) 14
research article (14) 14
safety (14) 14
drug administration schedule (13) 13
drug combinations (13) 13
aged, 80 and over (12) 12
efficacy (12) 12
highly active antiretroviral therapy (12) 12
ribavirin - therapeutic use (12) 12
antiretroviral therapy, highly active (11) 11
cohort studies (11) 11
darunavir (11) 11
emtricitabine (11) 11
follow-up studies (11) 11
general & internal medicine (11) 11
genetic aspects (11) 11
health care sciences & services (11) 11
hiv infections - immunology (11) 11
infections (11) 11
medicine & public health (11) 11
medicine, general & internal (11) 11
neurosciences & neurology (11) 11
prevalence (11) 11
ribavirin (11) 11
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (282) 282
Portuguese (2) 2
Spanish (2) 2
French (1) 1
German (1) 1
Japanese (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 03/2015, Volume 385, Issue 9973, pp. 1075 - 1086
Journal Article
Journal of acquired immune deficiency syndromes (1999), ISSN 1525-4135, 03/2010, Volume 53, Issue 3, pp. 323 - 332
BACKGROUND:Once-daily atazanavir/ritonavir demonstrated similar antiviral efficacy to twice-daily lopinavir/ritonavir over 48 weeks, with less gastrointestinal disturbance and a better lipid profile, in treatment-naive patients... 
CASTLE study | HIV-1 | Combination antiretroviral therapy | Atazanavir/ritonavir | Treatment-naive patients | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Male | RNA, Viral - blood | Oligopeptides - adverse effects | Viral Load | Anti-HIV Agents - administration & dosage | Tenofovir | Young Adult | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | HIV-1 - isolation & purification | Lipids - blood | Aged, 80 and over | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Antiretroviral Therapy, Highly Active - methods | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Ritonavir - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Lopinavir | Pyrimidinones - adverse effects | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Aged | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Deoxycytidine - analogs & derivatives | Studies | Antiretroviral drugs | Drug therapy | Ribonucleic acid--RNA | Human immunodeficiency virus--HIV | Index Medicus | AIDS/HIV
Journal Article
AIDS (London), ISSN 0269-9370, 03/2014, Volume 28, Issue 5, pp. 717 - 725
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 09/2015, Volume 61, Issue 5, pp. 829 - 836
Journal Article
Cell host & microbe, ISSN 1931-3128, 10/2018, Volume 24, Issue 4, pp. 600 - 610.e4
Journal Article
Journal of acquired immune deficiency syndromes (1999), ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 77 - 85
BACKGROUND:STARTMRK, a phase III noninferiority trial of raltegravir-based versus efavirenz-based therapy in treatment-naive patients, remained blinded until its conclusion at 5 years... 
raltegravir | HIV | STARTMRK | efavirenz | treatment naive | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | HIV-1 | Oxazines | Humans | Male | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Pyrrolidinones - therapeutic use | Benzoxazines - adverse effects | Treatment Outcome | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Drug Combinations | Clinical trials | Patient safety | Antiretroviral drugs | Drug therapy | Comparative analysis | Human immunodeficiency virus--HIV | Index Medicus | AIDS/HIV | Indexing in process
Journal Article
Journal Article
Journal of hepatology, ISSN 0168-8278, 08/2014, Volume 61, Issue 2, pp. 219 - 227
Journal Article